Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by BioTeckon Jul 14, 2022 1:49am
401 Views
Post# 34823129

RE:RE:Echelon Confirms $3.75 Target

RE:RE:Echelon Confirms $3.75 TargetAll the positive news that is being spread is being done through unofficial channels. I don't think it's totally belly up yet but had the Evotec deal been sealed a few months earlier, we would have been able to get out at a decent price. Things could still get a lot more ugly in the market before they turn around. Timing couldn't have been worse. Bad market, warrants, etc etc. A handfull of us called this was going to happen. Not because we have gypsy powers but it was just that obvious.

This is another 2 year hold now and IF the conformal coating works with Evo cells, we could still have a chance but those are big ifs. If it was as sure of a bet as people think and as management says, we wouldn't be here complaining about the dollar share price. Vertex should just offer us 1.50 and be the only horse in the race and hopefully get a cure for the diabetics.
<< Previous
Bullboard Posts
Next >>